BSG005 / Biosergen - LARVOL DELTA

Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Biosergen AS | Trial completion date: Jun 2025 ➔ Apr 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Infectious Disease

In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models. (PubMed, Antimicrob Agents Chemother) - "BSG005 demonstrated potent activity against a variety of fungal pathogens in the neutropenic mouse models. Cmax/MIC PK/PD targets were numerically lower than other polyene studies using the same infection models."

Journal • PK/PD data • Preclinical • Candidiasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients with Invasive Fungal Infection (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Biosergen AS

New P1/2 trial • Infectious Disease

Reviving the interest in the versatile drug nystatin: a multitude of strategies to increase its potential as an effective and safe antifungal agent. (PubMed, Adv Drug Deliv Rev) - "The unsuccessful previous attempts at developing parenteral formulations of nystatin or even the withdrawal of a nystatin-loaded multilamellar liposome should not divert research away from this drug. In fact, the interest in nystatin ought to be reawakened with the ongoing clinical trials on the promising nystatin-like genetically engineered derivate BSG005."

Journal • Review • Infectious Disease

A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005. (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Biosergen AS | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2022 ➔ May 2023 | Trial primary completion date: Mar 2022 ➔ Mar 2023

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease

"Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus. https://t.co/hjunuZIugg" (@CisionNews)

Infectious Disease